KNC Laboratories Co., Ltd.

Business Details

Kobe Natural Products Chemicals provides integrated contract synthesis services for organic chemicals used in pharmaceuticals, information/electronics, agrochemicals, and other fields, spanning from the research stage through to the mass production stage. The company employs a "Stage-Up Growth" model that offers solutions tailored to each customer's product development stage, and has consistently maintained a mass-production-stage sales ratio of over 60%. It is a non-consolidated single-segment company comprising three business divisions: Functional Materials, Pharmaceutical, and Bio.

Recent Overview

All three divisions posted higher sales, and operating profit rose 32.7% year on year, marking a strong recovery. Full-year earnings guidance remains undetermined due to Middle East tensions

In FY2026 (ending March 2026), net sales reached ¥9,093 million (up 11.2% year on year) and operating profit reached ¥1,024 million (up 32.7% year on year), staging a strong recovery from the sharp profit decline of the previous fiscal year. The Bio division led the way with growth of 26.5% year on year, aided by the commencement of operations at the KNC Bio Research Center Building D. The effect of increased sales outweighed the rise in fixed costs (depreciation expense of ¥1,179 million, versus ¥830 million in the prior period). On the other hand, citing supply disruption risk for petrochemical products resulting from the de facto closure of the Strait of Hormuz since March 2026, the company has left its full-year earnings forecast for FY2027 (ending March 2027) undetermined, disclosing only its first-quarter outlook (net sales of ¥2,000 million and operating profit of ¥95 million).

Key Products

Growth Drivers

• Continued high growth in the Bio Business Division (up 26.5% year on year in FY2026, ending March 2026) and expanded production capacity from the commencement of operations at the KNC Bio Research Center Building D
• Booking of sales from a large-scale mass-production-stage project and favorable progress of development-stage projects in the Pharmaceutical Business Division (up 11.9% year on year)
• Contribution to next-period sales from advance production of a large-scale project in the Functional Materials Business Division scheduled to be booked in the following fiscal year
• Stable maintenance of a mass-production-stage sales ratio exceeding 60% under the Stage-Up Growth model
• Continued trend of outsourcing R&D in the contract organic chemicals industry, alongside expanding demand driven by technological specialization and deepening
• Building a foundation for future growth through active investment in facilities and human resources (capital expenditures on tangible fixed assets of ¥2,626 million in FY2026, ending March 2026)

Risks

• Risk of supply disruption to key raw materials and petrochemical products due to heightened tensions in the Middle East (de facto closure of the Strait of Hormuz), the main reason the full-year forecast for FY2027 (ending March 2027) remains undetermined
• High dependence on customers' development and production plans, with changes to such plans directly affecting business performance
• Profit pressure from increased depreciation expense associated with the new building coming online (¥1,179 million in FY2026, ending March 2026, up 42.2% year on year) and rising costs for personnel training and recruitment
• Increased interest-bearing debt associated with large-scale capital expenditures (long-term borrowings balance of ¥2,494 million plus ¥1,103 million due within one year) and the resulting increase in financial burden
• Risk of fluctuation in gross margin due to changes in product mix
• Downward pressure on the domestic economy from macro risks such as U.S. trade policy and rising prices, and the resulting restraint on customers' capital expenditure and R&D investment
• Risk of sales concentration among specific customers